This retrospective cohort study evaluates real-world health outcomes in patients with T1D and T2D initiating Gla-300 or Gla-100 as part of their usual therapy in the largest specialist-led clinic group in Canada, between January 2015 and August 2017. The primary outcome was HbA1c change at 3-6 months. Four separate cohorts were evaluated. In the T1D cohort, 299 patients transferred from Gla-100 to Gla-300 had a significant HbA1c reduction of -0.2 ± 1.2%, with no change in weight, hypoglycemia or basal insulin dose (Table). Similarly, 488 patients with T2D transferred from Gla-100 to Gla-300 had a significant HbA1c reduction of -0.47 ± 1.37%, with no change in weight, hypoglycemia or basal insulin dose. In patients with T2D transferred from NPH or detemir (n=343), Gla-300 had a significantly greater reduction in HbA1c than Gla-100 (-0.30 ± 2.2%), with no change in weight, hypoglycemia or basal insulin dose in either group. For insulin-naïve T2D patients (n=1448), there were no significant differences between Gla-300 and Gla-100 in adjusted HbA1c or weight. Patients with T1D and T2D in a national specialist-led registry, who transferred from their usual basal insulin to Gla-300, significantly reduced their HbA1c, without increasing weight, basal insulin dose, nor hypoglycemia incidence.
A. Abitbol: Research Support; Self; JDRF, JA DeSeve Foundation, Lexicon Pharmaceuticals, Inc., Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; GlaxoSmithKline plc., Merck & Co., Inc.. Consultant; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Pfizer Inc., AstraZeneca. Consultant; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; Senseonics, Gilead Sciences, Inc.. Speaker's Bureau; Self; Amgen Inc., Janssen Pharmaceuticals, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc.. Employee; Self; LMC Diabetes & Endocrinology. Speaker's Bureau; Self; LMC Diabetes & Endocrinology, Valeant Pharmaceuticals International, Inc.. Consultant; Self; Valeant Pharmaceuticals International, Inc.. R.E. Brown: None. D. Jiandani: None. L. Sauriol: Employee; Self; Sanofi. R. Aronson: Other Relationship; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Sanofi, AstraZeneca. Research Support; Self; Eli Lilly and Company, Becton, Dickinson and Company, Merck & Co., Inc., Senseonics, Boehringer Ingelheim Pharmaceuticals, Inc..
